Skip to main content
Springer logoLink to Springer
. 2019 Mar 21;39(4):419. doi: 10.1007/s40261-019-00780-x

Correction to: Neratinib in Early-Stage Breast Cancer: A Profile of Its Use in the EU

Sohita Dhillon 1,
PMCID: PMC6443610  PMID: 30900188

Correction to: Clinical Drug Investigation (2019) 39:221–229 10.1007/s40261-018-0741-2

The article Neratinib in Early-Stage Breast Cancer: A Profile of Its Use in the EU, written by Sohita Dhillon, was originally published Online First without open access. After publication in volume 39, issue 2, page 221–229 Puma Biotechnology, Inc. requested that the article be Open Choice to make the article an open access publication. Post-publication open access was funded by Puma Biotechnology, Inc. The article is forthwith distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, duplication, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license and indicate if changes were made.

The original article has been corrected.


Articles from Clinical Drug Investigation are provided here courtesy of Springer

RESOURCES